文献速递神经肿瘤

成人弥漫性胶质瘤替莫唑胺所致严重骨髓毒性的临床与遗传预测因素:病例对照研究

Clinical and genetic predictors of temozolomide-induced severe myelotoxicity in adult diffuse glioma: a case-control study.
PubMed 文献 · J Neurooncol · 2026-02-20

该病例对照研究纳入46例发生≥3级骨髓毒性的成人弥漫性胶质瘤病例与50例0–1级对照,分析临床与遗传因素与替莫唑胺所致严重骨髓毒性的关联。结果显示女性、体表面积≤1.6m2及MGMT基因L84F变异T等位基因与≥3级骨髓毒性显著相关,倾向性评分匹配后L84F变异T等位基因关联仍显著。

要点

  • 女性、BSA≤1.6m2及MGMT L84F变异T等位基因与TMZ≥3级骨髓毒性相关
  • 倾向性评分匹配后L84F变异T等位基因与严重骨髓毒性仍显著相关
  • 治疗前可结合性别、BSA与L84F基因型识别高风险患者

核心结论

  • 成人弥漫性胶质瘤中,TMZ所致≥3级骨髓毒性与女性、BSA≤1.6m2及MGMT L84F变异T等位基因显著相关。

研究设计与样本

  • 病例对照研究,纳入46例≥3级骨髓毒性病例与50例0–1级骨髓毒性对照。
  • 采用卡方检验或Fisher精确检验分析关联,以OR及95%CI表达。
  • 基于年龄、性别、血小板计数和BSA估计倾向性评分,按1:1最近邻匹配(病例26例、对照26例)。

主要发现

  • 女性与TMZ所致≥3级骨髓毒性相关(OR=5.39,95%CI:2.25–12.94;p<0.001)。
  • BSA≤1.6m2与≥3级骨髓毒性相关(OR=3.79,95%CI:1.52–9.48;p=0.005)。
  • L84F变异T等位基因与≥3级骨髓毒性相关(OR=5.04,95%CI:2.07–12.27;p=0.001)。
  • 倾向性评分匹配后,L84F变异T等位基因与≥3级骨髓毒性仍正相关(OR=4.55,95%CI:1.37–15.08;p=0.01)。

关键数值与推荐

  • 严重骨髓毒性定义为≥3级骨髓毒性,对照为0–1级骨髓毒性。
  • BSA阈值≤1.6m2与TMZ所致≥3级骨髓毒性显著相关。
  • L84F为MGMT基因单核苷酸多态性,其变异T等位基因与严重骨髓毒性相关。

临床怎么用

  • 对成人弥漫性胶质瘤患者使用TMZ前,可关注女性、BSA≤1.6m2及MGMT L84F变异T等位基因等风险因素。
  • 对具备上述风险因素者,可加强骨髓毒性监测。

局限性

  • 原文摘要未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Several clinical and genetic factors including single nucleotide polymorphisms (SNP) in the O6-methylguanine-DNA methyltransferase (MGMT) gene are associated with increased risk of temozolomide (TMZ) induced myelotoxicity. We have previously reported substantially higher frequency of variant T allele of L84F (SNP in MGMT gene) in Indian patients with clinically relevant myelotoxicity compared to normal South Asian population. We now report findings from our case-control study correlating clinical and genetic factors with TMZ-induced ≥grade 3 myelotoxicity in adult diffuse glioma. METHODS: We enrolled 46 cases (≥ grade 3 myelotoxicity) and 50 controls (grade 0–1 myelotoxicity) in the present case-control study. Association of various clinical and genetic characteristics with TMZ-induced severe myelotoxicity was analysed using chi-square test and Fisher’s exact test as appropriate and expressed as odds ratio (OR) with 95% confidence intervals (95%CI). For matched-pair analysis, propensity scores were estimated using logistic regression model based on baseline covariates – age, gender, platelet count, and body-surface area (BSA). Cases (n = 26 and controls (n = 26) were matched in 1:1 ratio using nearest-neighbour matching method without replacement. RESULTS: We found statistically significant association of TMZ-induced ≥grade 3 myelotoxicity for female gender (OR = 5.39, 95%CI: 2.25–12.94; p < 0.001), BSA ≤ 1.6m2 (OR = 3.79, 95%CI: 1.52–9.48; p = 0.005), and presence of variant T allele in L84F (OR = 5.04, 95%CI: 2.07–12.27; p = 0.001). Propensity score matching confirmed positive correlation of ≥grade 3 myelotoxicity with variant T allele in L84F (OR = 4.55, 95%CI: 1.37–15.08; p = 0.01). CONCLUSIONS: Our case-control study reports significant association between TMZ-induced severe myelotoxicity and various clinical and genetic factors in accordance with findings from previous studies.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Malhotra R, Moitra P, Chatterjee A, et al. Clinical and genetic predictors of temozolomide-induced severe myelotoxicity in adult diffuse glioma: a case-control study. J Neurooncol. 2026. PMID: 41718852. doi:10.1007/s11060-026-05474-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。